Sort by
Refine Your Search
-
for the development of a sensor technology to detect microRNAs in biological samples. Specifically, the PRF will fabricate sensor on a paper platform and qualitatively and quantitatively test microRNA presence in
-
for Experiential AI is built around the challenges and opportunities made possible by human-machine collaboration. The Institute provides a framework to design, implement, and scale AI-driven technologies in ways
-
fellow will develop their own research as well as support on-going research projects that include the design, development, and evaluation of civic technologies with communities in the Boston region
-
technologies with communities in the Boston region. The postdoctoral fellow will contribute to advancing our understanding of how digital technologies can support different forms of civic action - from
-
. Mechanobiology in aging in the musculoskeletal system or the cardiovascular system: this area focuses on the application of mechanobiology technology and discovery to the aging research. 2. Immunomechanobiology
-
challenges and opportunities made possible by human-machine collaboration. The Institute provides a framework to design, implement, and scale AI-driven technologies in ways that make a true difference to
-
challenges and opportunities made possible by human-machine collaboration. The Institute provides a framework to design, implement, and scale AI-driven technologies in ways that make a true difference to
-
health risks or co-occurring adversities; mental health; risk and resilience in response to race- or weight-based stigma and discrimination; use of artificial intelligence (AI) and technology to address
-
transpacific dynamics. We are especially interested in applicants with specialties in the following subfields that engage with the University’s research foci: science and technology; environmental studies
-
of specific proteins in a cancer cell’s nucleus with SINE technology. Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies